Publications by authors named "Sneha Purushotham"
Background: Clinical decision support systems (CDSSs) are designed to assist in health care delivery by supporting medical practice with clinical knowledge, patient information, and other relevant types of health information. CDSSs are integral parts of health care technologies assisting in disease management, including diagnosis, treatment, and monitoring. While electronic medical records (EMRs) serve as data repositories, CDSSs are used to assist clinicians in providing personalized, context-specific recommendations derived by comparing individual patient data to evidence-based guidelines.
View Article and Find Full Text PDFArticle Synopsis
- * A systematic review identified that IMD incidence and mortality rates are higher in poorer neighborhoods and among specific racial and socioeconomic groups, with differences in vaccination rates based on income and education levels.
- * To address these inequalities, health policymakers should strengthen vaccination recommendations and improve public knowledge about IMD and its vaccines, especially for underrepresented and underserved populations.
Article Synopsis
- β-Thalassemia is a lifelong inherited blood disorder that requires ongoing management and leads to significant indirect costs and a burden on patients and caregivers.
- The study conducted a systematic review of the literature from 2010 to 2020, including 75 publications, to assess health-related quality of life (HRQoL) and costs associated with the condition.
- Results showed that patients lose an average of 15.6 to 35 days yearly due to transfusion-related absenteeism, and those with non-transfusion-dependent β-thalassemia experience worse HRQoL compared to those with transfusion-dependent forms, highlighting a need for better treatments.
Background: Patients with mild or mild-to-moderate chronic obstructive pulmonary disease (COPD), defined as Global Initiative for Chronic Obstructive Lung Disease (GOLD) group A/B, are regarded as having a lower risk of experiencing multiple or severe exacerbations compared with patients classified as GOLD group C/D. Current guidelines suggest that patients in GOLD A/B should commence treatment with a bronchodilator; however, some patients within this population who have a higher disease burden may benefit from earlier introduction of dual bronchodilator or inhaled corticosteroid-containing therapies. This study aimed to provide research-based insights into the burden of disease experienced by patients classified as GOLD A/B, and to identify characteristics associated with poorer outcomes.
View Article and Find Full Text PDF